Dysregulation of Placental miRNA in Maternal Obesity Is Associated With Pre- and Postnatal Growth
Por:
Carreras-Badosa G, Bonmatí A, Ortega FJ, Mercader JM, Guindo-Martínez M, Torrents D, Prats-Puig A, Martinez-Calcerrada JM, DE Zegher F, Ibañez-Toda L, Fernandez-Real JM, Lopez-Bermejo A and Bassols J
Publicada:
1 jul 2017
Ahead of Print:
20 mar 2017
Resumen:
Context: Human placenta exhibits a specific microRNA (miRNA) expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders such as preeclampsia and intrauterine growth restriction and are potential biomarkers for these pathologies.
Objective: To study the placental miRNA profile in pregnant women with pregestational overweight/obesity (preOB) or gestational obesity (gestOB) and explore the associations between placental miRNAs dysregulated in maternal obesity and prenatal and postnatal growth.
Methods: TaqMan Low Density Arrays and real-time polymerase chain reaction were used to profile the placental miRNAs in 70 pregnant women (20 preOB, 25 gestOB, and 25 control). Placentas and newborns were weighed at delivery, and infants were weighed at 1, 4, and 12 months of age.
Results: Eight miRNAs were decreased in placentas from preOB or gestOB (miR-100, miR-1269, miR1285, miR-181, miR-185, miR-214, miR-296, and miR-487) (all P < 0.05). Among them, miR-100, miR1285, miR-296, and miR-487 were associated with maternal metabolic parameters (all P < 0.05) and were predictors of lower birth weight (all P < 0.05; R-2 > 30%) and increased postnatal weight gain (all P < 0.05; R-2 > 20%). In silico analysis showed that these miRNAs were related to cell proliferation and insulin signaling pathways. miR-296 was also present in plasma samples and associated with placental expression and prenatal and postnatal growth parameters (all P < 0.05).
Conclusions: We identified a specific placental miRNA profile in maternal obesity. Placental miRNAs dysregulated in maternal obesity may be involved in mediation of growth-promoting effects of maternal obesity on offspring and could be used as early markers of prenatal and postnatal growth.
Filiaciones:
Carreras-Badosa G:
Pediatric Endocrinology group, (Girona Biomedical Research Institute) IDIBGI, Dr. Trueta University Hospital, Girona 17007, Spain
Bonmatí A:
Department of Gynecology, Dr. Trueta University Hospital, Girona 17007, Spain
Ortega FJ:
Diabetes, Endocrinology and Nutrition Group, (Girona Biomedical Research Institute) IDIBGI, Dr. Trueta University Hospital, CIBERobn, Girona 17007, Spain
Mercader JM:
Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, Barcelona 08028, Spain
Guindo-Martínez M:
Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, Barcelona 08028, Spain
Torrents D:
Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, Barcelona 08028, Spain
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
Prats-Puig A:
Department of Physical Therapy, EUSES University School, University of Girona, 17007 Girona, Spain
Martinez-Calcerrada JM:
Institute of Legal Medicine of Catalonia, 17001 Girona, Spain
DE Zegher F:
Department of Development & Regeneration, University of Leuven, 3000 Leuven, Belgium
Ibañez-Toda L:
Endocrinology, Hospital Sant Joan de Déu, University of Barcelona, 08950 Esplugues, Barcelona, and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain
Fernandez-Real JM:
Diabetes, Endocrinology and Nutrition Group, (Girona Biomedical Research Institute) IDIBGI, Dr. Trueta University Hospital, CIBERobn, Girona 17007, Spain
Lopez-Bermejo A:
Pediatric Endocrinology group, (Girona Biomedical Research Institute) IDIBGI, Dr. Trueta University Hospital, Girona 17007, Spain
Bassols J:
Pediatric Endocrinology group, (Girona Biomedical Research Institute) IDIBGI, Dr. Trueta University Hospital, Girona 17007, Spain
Bronze
|